Enanta Pharmaceuticals Announces the Planned Retirement of Chief Medical Officer Nathalie Adda, M.D.
July 14 2021 - 5:30PM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage
biotechnology company dedicated to creating small molecule drugs
for viral infections and liver diseases, today announced that
Nathalie Adda, M.D., Senior Vice President and Chief Medical
Officer, will retire from Enanta in February 2022 and continue to
serve as a consultant to the company thereafter. Enanta is
commencing a search to identify Dr. Adda’s successor.
“On behalf of the entire Enanta team and our Board of Directors,
I thank Nathalie for her dedication to the company,” said Jay R.
Luly, Ph.D., President and Chief Executive Officer of Enanta
Pharmaceuticals. “During her tenure since joining us in 2015,
Nathalie has been responsible for building and overseeing Enanta’s
Clinical and Regulatory Department. Nathalie’s significant
contributions have supported the growth of our robust pipeline of
four clinical candidates across respiratory syncytial virus,
hepatitis B virus and non-alcoholic steatohepatitis. Under her
expertise and direction, Enanta has progressed candidates for these
indications into the clinic and is advancing a fifth into a Phase 1
study soon. We wish Nathalie the very best in her retirement and
are grateful that we will continue to benefit from her deep
knowledge through her consulting role.”
“Working with the entire Enanta team to advance our vision of
becoming a leader in the discovery and development of small
molecule drugs for the treatment of viral infections and liver
diseases has been a privilege and deeply rewarding, and I am
grateful for the opportunity to have built and led the Clinical and
Regulatory team to achieve several important milestones to further
our vision,” said Nathalie Adda, M.D., Senior Vice President and
Chief Medical Officer of Enanta Pharmaceuticals. “I believe Enanta
is well-positioned to progress not only these clinical programs,
but also its entire pipeline, to bring meaningful new treatments to
patients.”
About Enanta Enanta is using its robust, chemistry-driven
approach and drug discovery capabilities to become a leader in the
discovery and development of small molecule drugs for the treatment
of viral infections and liver diseases. Enanta’s research and
development efforts have produced clinical candidates for the
following disease targets: respiratory syncytial virus (RSV),
hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH).
Enanta is also conducting research in SARS-CoV-2 (COVID-19) and
human metapneumovirus (hMPV).
Enanta’s research and development activities are funded by
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta, is sold by AbbVie in numerous countries as
part of its leading treatment for chronic HCV infection under the
tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.)
(glecaprevir/pibrentasvir). Please visit www.enanta.com for more
information.
Forward Looking Statements Disclaimer
This press release contains forward-looking statements,
including statements with respect to the prospects for further
development of Enanta’s clinical pipeline. Statements that are not
historical facts, are based on management’s current expectations,
estimates, forecasts and projections about Enanta’s business and
the industry in which it operates and management’s beliefs and
assumptions. The statements contained in this release are not
guarantees of future performance and involve certain risks,
uncertainties and assumptions, which are difficult to predict.
Therefore, actual outcomes and results may differ materially from
what is expressed in such forward-looking statements. Important
factors and risks that may affect actual results include: the
development risks of early stage clinical development in the
disease areas in Enanta’s research and development pipeline; the
impact of development, regulatory and marketing efforts of others
with respect to competitive treatments; Enanta’s limited clinical
development experience; Enanta’s need to attract and retain senior
management and key scientific personnel; Enanta’s need to obtain
and maintain patent protection for its product candidates and avoid
potential infringement of the intellectual property rights of
others; and other risk factors described or referred to in “Risk
Factors” in Enanta’s most recent Form 10-Q for the quarter ended
March 31, 2021 and other periodic reports filed more recently with
the Securities and Exchange Commission. Enanta cautions investors
not to place undue reliance on the forward-looking statements
contained in this release. These statements speak only as of the
date of this release, and Enanta undertakes no obligation to update
or revise these statements, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210714005842/en/
Media and Investor Contact Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2023 to Apr 2024